By the same authors

From the same journal

Opportunities for improving the efficiency of paediatric HIV treatment programmes: lessons from the ARROW trial

Research output: Contribution to journalArticle

Published copy (DOI)

Author(s)

  • Paul A Revill
  • Simon Walker
  • Travor Mabugu
  • Kusum J Nathoo
  • Peter Mugyenyi
  • Adeodata Kekitinwa
  • Paula Munderi
  • Mutsawashe Bwakura-Dangarembizi
  • Victor Musiime
  • Sabrina Bakeera-Kitaka
  • Patricia Nahirya-Ntege
  • A Sarah Walker
  • Mark J Sculpher
  • Diana M Gibb

Department/unit(s)

Publication details

JournalAIDS (London, England)
DatePublished - 14 Jan 2015
Issue number2
Volume29
Pages (from-to)201–210
Original languageEnglish

Abstract

OBJECTIVES:: To conduct two economic analyses addressing whether to: routinely monitor HIV-infected children on antiretroviral therapy (ART) clinically or with laboratory tests; continue or stop cotrimoxazole prophylaxis when children become stabilized on ART.

DESIGN AND METHODS:: The ARROW randomized trial investigated alternative strategies to deliver paediatric ART and cotrimoxazole prophylaxis in 1206 Ugandan/Zimbabwean children. Incremental cost-effectiveness and value of implementation analyses were undertaken. Scenario analyses investigated whether laboratory monitoring (CD4 tests for efficacy monitoring; haematology/biochemistry for toxicity) could be tailored and targeted to be delivered cost-effectively. Cotrimoxazole use was examined in malaria-endemic and non-endemic settings.

RESULTS:: Using all trial data, clinical monitoring delivered similar health outcomes to routine laboratory monitoring, but at a reduced cost, so was cost-effective. Continuing cotrimoxazole improved health outcomes at reduced costs.Restricting routine CD4 monitoring to after 52 weeks following ART initiation and removing toxicity testing was associated with an incremental cost-effectiveness ratio of $6084 per quality-adjusted life-year (QALY) across all age groups, but was much lower for older children (12+ years at initiation; incremental cost-effectiveness ratio = $769/QALY).Committing resources to improve cotrimoxazole implementation appears cost-effective. A healthcare system that could pay $600/QALY should be willing to spend up to $12.0 per patient-year to ensure continued provision of cotrimoxazole.

CONCLUSION:: Clinically driven monitoring of ART is cost-effective in most circumstances. Routine laboratory monitoring is generally not cost-effective at current prices, except possibly CD4 testing amongst adolescents initiating ART.Committing resources to ensure continued provision of cotrimoxazole in health facilities is more likely to represent an efficient use of resources.

Discover related content

Find related publications, people, projects, datasets and more using interactive charts.

View graph of relations